Protocol Ledger

NCT05489887 · Phase II · RECRUITING

Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Interventional Phase II clinical trial protocol NCT05489887 sponsored by Giselle Sholler in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-09-14 Enrollment: 93 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05489887
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)93 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05489887
Protocol FieldVerified Registry Value
NCT IdentifierNCT05489887
Consolidated Lead SponsorGiselle Sholler
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment93 participants (ESTIMATED)
Registered Start Date2022-09-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05489887
Hospital Research SiteLocationSite Profile
Arkansas Children's HospitalLittle Rock, AROpen Hospital Dossier ->
UCSF Benioff Children's Hospital OaklandOakland, CAOpen Hospital Dossier ->
Rady Children's HospitalSan Diego, CAOpen Hospital Dossier ->
University of FloridaGainesville, FLOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI